{"transactions":[{"id":681557,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2026-08-19T23:00:08.000Z","date":"2026-08-17","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 5,000 shares of common stock (the \"Options\") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 5,000 shares of common stock (the \"Options\") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include the stock options previously granted to the Reporting Person."}],"balance_after":5000,"derivative":{"exercise_price":1.36,"expiration_date":"2036-08-17","underlying":"Common stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001493152-26-039288","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226039288/ownership.xml","form_type":"4"}},{"id":735071,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T23:39:19.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant."}],"balance_after":7000,"derivative":{"exercise_price":7.13,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001420987-26-000004","document":"form4-06172026_110615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000142098726000004/form4-06172026_110615.xml","form_type":"4"}},{"id":1056886,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2025-08-26T00:47:41.000Z","date":"2025-08-21","kind":"purchase","planned":false,"acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The common stock and warrants were acquired by the reporting person in a public offering conducted by the Issuer that was closed on August 21, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant."}],"balance_after":75000,"derivative":{"exercise_price":2,"exercise_date":"2025-08-21","expiration_date":"2030-08-21","underlying":"Common stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001641172-25-025448","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225025448/ownership.xml","form_type":"4"}},{"id":1056885,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-26T00:47:41.000Z","date":"2025-08-21","kind":"purchase","planned":false,"acquired":true,"shares":75000,"price":2,"value":150000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The common stock and warrants were acquired by the reporting person in a public offering conducted by the Issuer that was closed on August 21, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant."}],"balance_after":76134,"source":{"system":"sec-edgar","filing":"0001641172-25-025448","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225025448/ownership.xml","form_type":"4"}},{"id":1087410,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2025-07-16T00:42:59.000Z","date":"2025-07-09","kind":"grant","planned":false,"acquired":true,"shares":164493,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On July 15, 2025, the Reporting Person was issued a non-qualified stock option to purchase 164,493 shares of common stock (the \"Options\") at an exercise price of $0.70 per share (equal to the closing price on the grant date, July 9, 2025) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 15, 2025, the Reporting Person was issued a non-qualified stock option to purchase 164,493 shares of common stock (the \"Options\") at an exercise price of $0.70 per share (equal to the closing price on the grant date, July 9, 2025) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan."}],"balance_after":164493,"derivative":{"exercise_price":0.7,"expiration_date":"2035-07-09","underlying":"Common stock","underlying_shares":164493},"source":{"system":"sec-edgar","filing":"0001641172-25-019802","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225019802/ownership.xml","form_type":"4"}},{"id":1096548,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T20:33:27.000Z","date":"2025-06-30","kind":"purchase","planned":false,"acquired":true,"shares":23567,"price":5.07,"value":119484.69,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $4.935 to $5.25. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a 1-for-25 reverse stock split effective on June 16, 2025."}],"balance_after":39666,"source":{"system":"sec-edgar","filing":"0001415889-25-019067","document":"form4-07022025_080721.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000141588925019067/form4-07022025_080721.xml","form_type":"4"}},{"id":1120346,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T20:18:56.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of four equal quarterly installments measured from the date of grant or the date of the next annual meeting of stockholders, subject to the reporting person's continued service at each applicable vest date."}],"balance_after":120000,"derivative":{"exercise_price":0.3051,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001415889-25-015985","document":"form4-06062025_080651.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000141588925015985/form4-06062025_080651.xml","form_type":"4"}},{"id":1194062,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-24T13:00:05.000Z","date":"2025-03-21","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":0.3408,"value":17040.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $0.3341 to $0.3466. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":373722,"source":{"system":"sec-edgar","filing":"0001415889-25-008823","document":"form4-03242025_090301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000141588925008823/form4-03242025_090301.xml","form_type":"4"}},{"id":1194061,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-24T13:00:05.000Z","date":"2025-03-20","kind":"purchase","planned":false,"acquired":true,"shares":250000,"price":0.352,"value":88000.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $0.3499 to $0.3593. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":323722,"source":{"system":"sec-edgar","filing":"0001415889-25-008823","document":"form4-03242025_090301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000141588925008823/form4-03242025_090301.xml","form_type":"4"}},{"id":1386745,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2024-10-16T01:14:35.000Z","date":"2024-09-20","kind":"grant","planned":false,"acquired":true,"shares":20217,"ownership":{"direct":true},"footnotes":[{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the \"Options\") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the \"Grant Date\"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the \"Options\") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the \"Grant Date\"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the \"Options\") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the \"Grant Date\"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 11, 2024, pursuant to the issuer's 2023 Equity Incentive Plan, the reporting person was issued a non-qualified stock option to purchase 20,217 shares of common stock (the \"Options\") at an exercise price of $1.09, which is the closing price of the issuer's common stock on the grant date, September 20, 2024 (the \"Grant Date\"). The Options shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the Grant Date."}],"balance_after":20217,"derivative":{"exercise_price":1.09,"expiration_date":"2034-09-20","underlying":"Common stock","underlying_shares":20217},"source":{"system":"sec-edgar","filing":"0001493152-24-041201","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224041201/ownership.xml","form_type":"4"}},{"id":1463322,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-03T00:20:57.000Z","date":"2024-06-28","kind":"grant","planned":false,"acquired":true,"shares":79687,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") on June 28, 2024 (the \"Grant Date\"), pursuant to the Issuer's 2023 Equity Incentive Plan and subject to the conditions of a Restricted Stock Unit Award Agreement, in a transaction exempt under Rule 16b-3 to the Reporting Person, who is a non-employee director with the Issuer, in connection with services for the Issuer's second fiscal quarter. Each RSU represents a contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUs fully vested on the Grant Date."}],"balance_after":1071781,"source":{"system":"sec-edgar","filing":"0001493152-24-026115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224026115/ownership.xml","form_type":"4"}},{"id":1463320,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-03T00:14:26.000Z","date":"2024-03-29","kind":"grant","planned":false,"acquired":true,"shares":28207,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") on March 29, 2024 (the \"Grant Date\"), pursuant to the Issuer's 2023 Equity Incentive Plan and subject to the conditions of a Restricted Stock Unit Award Agreement, in a transaction exempt under Rule 16b-3 to the Reporting Person, who is a non-employee director with the Issuer, in connection with services for the Issuer's first fiscal quarter. Each RSU represents a contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUs fully vested on the Grant Date."}],"balance_after":992094,"source":{"system":"sec-edgar","filing":"0001493152-24-026108","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224026108/ownership.xml","form_type":"4"}},{"id":1488970,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T00:00:19.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest on the earlier of June 16, 2025 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":70000,"derivative":{"exercise_price":1.21,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001415889-24-015859","document":"form4-06062024_080616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000141588924015859/form4-06062024_080616.xml","form_type":"4"}},{"id":1490250,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2024-06-05T20:15:09.000Z","date":"2024-06-03","kind":"grant","planned":false,"acquired":true,"shares":548000,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On May 31, 2024, the Reporting Person and the Issuer entered into an inducement offer letter agreement (the \"Inducement Agreement\") providing for the immediate exercise of some or all of certain Series B warrants and Series C warrants, at an initial exercise price of $0.60, previously purchased in the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"), at a reduced exercise price of $0.20 (the \"Exercise\"). Pursuant to the Inducement Agreement, the Issuer also issued Series D common stock purchase warrants (\"New Series D Warrants\") in consideration for the Exercise. The Offering closed on June 3, 2024."},{"field":"security","element":"securityTitle","label":"F6","text":"Represents Series D warrants to purchase up to an aggregate of 548,000 shares of common stock at an exercise price of $0.30 per share (the \"Series D Warrants\") pursuant to the Inducement Agreement. The Series D Warrants will be initially exercisable upon receipt of stockholder approval as may be required by the rules of the NYSE American and will have a term of 66 months from the Issuance Date. The Series D Warrants were acquired in a transaction exempt under Rule 16b-3 and at the same offering terms as other investors in the Offering."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents Series D warrants to purchase up to an aggregate of 548,000 shares of common stock at an exercise price of $0.30 per share (the \"Series D Warrants\") pursuant to the Inducement Agreement. The Series D Warrants will be initially exercisable upon receipt of stockholder approval as may be required by the rules of the NYSE American and will have a term of 66 months from the Issuance Date. The Series D Warrants were acquired in a transaction exempt under Rule 16b-3 and at the same offering terms as other investors in the Offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Represents Series D warrants to purchase up to an aggregate of 548,000 shares of common stock at an exercise price of $0.30 per share (the \"Series D Warrants\") pursuant to the Inducement Agreement. The Series D Warrants will be initially exercisable upon receipt of stockholder approval as may be required by the rules of the NYSE American and will have a term of 66 months from the Issuance Date. The Series D Warrants were acquired in a transaction exempt under Rule 16b-3 and at the same offering terms as other investors in the Offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":548000,"derivative":{"exercise_price":0.3,"expiration_date":"2029-12-03","underlying":"Common Stock","underlying_shares":548000},"source":{"system":"sec-edgar","filing":"0001493152-24-022745","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224022745/ownership.xml","form_type":"4"}},{"id":1490249,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2024-06-05T20:15:09.000Z","date":"2024-06-03","kind":"exercise","planned":false,"acquired":true,"shares":375000,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On May 31, 2024, the Reporting Person and the Issuer entered into an inducement offer letter agreement (the \"Inducement Agreement\") providing for the immediate exercise of some or all of certain Series B warrants and Series C warrants, at an initial exercise price of $0.60, previously purchased in the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"), at a reduced exercise price of $0.20 (the \"Exercise\"). Pursuant to the Inducement Agreement, the Issuer also issued Series D common stock purchase warrants (\"New Series D Warrants\") in consideration for the Exercise. The Offering closed on June 3, 2024."},{"field":"security","element":"securityTitle","label":"F4","text":"Represents the exercise of 375,000 Series C warrants for 375,000 Series C Units, consisting of an aggregate of (i) 375,000 shares of common stock and (ii) Series C-1 Warrants to purchase up to an aggregate of 375,000 shares of common stock. The Series C Warrants are exercisable immediately upon issuance and will expire four months from April 18, 2024."},{"field":"security","element":"securityTitle","label":"F5","text":"The Series C-1 Warrants are exercisable immediately upon issuance and are exercisable for a term of 5 years from the Issuance Date at a reduced exercise price of $0.20."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Series C-1 Warrants are exercisable immediately upon issuance and are exercisable for a term of 5 years from the Issuance Date at a reduced exercise price of $0.20."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series C-1 Warrants are exercisable immediately upon issuance and are exercisable for a term of 5 years from the Issuance Date at a reduced exercise price of $0.20."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":375000,"derivative":{"exercise_price":0.2,"expiration_date":"2029-06-03","underlying":"Common Stock","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001493152-24-022745","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224022745/ownership.xml","form_type":"4"}},{"id":1490248,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2024-06-05T20:15:09.000Z","date":"2024-06-03","kind":"exercise","planned":false,"acquired":false,"shares":375000,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On May 31, 2024, the Reporting Person and the Issuer entered into an inducement offer letter agreement (the \"Inducement Agreement\") providing for the immediate exercise of some or all of certain Series B warrants and Series C warrants, at an initial exercise price of $0.60, previously purchased in the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"), at a reduced exercise price of $0.20 (the \"Exercise\"). Pursuant to the Inducement Agreement, the Issuer also issued Series D common stock purchase warrants (\"New Series D Warrants\") in consideration for the Exercise. The Offering closed on June 3, 2024."},{"field":"security","element":"securityTitle","label":"F4","text":"Represents the exercise of 375,000 Series C warrants for 375,000 Series C Units, consisting of an aggregate of (i) 375,000 shares of common stock and (ii) Series C-1 Warrants to purchase up to an aggregate of 375,000 shares of common stock. The Series C Warrants are exercisable immediately upon issuance and will expire four months from April 18, 2024."},{"field":"security","element":"securityTitle","label":"F5","text":"The Series C-1 Warrants are exercisable immediately upon issuance and are exercisable for a term of 5 years from the Issuance Date at a reduced exercise price of $0.20."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2024, the Reporting Person and the Issuer entered into an inducement offer letter agreement (the \"Inducement Agreement\") providing for the immediate exercise of some or all of certain Series B warrants and Series C warrants, at an initial exercise price of $0.60, previously purchased in the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"), at a reduced exercise price of $0.20 (the \"Exercise\"). Pursuant to the Inducement Agreement, the Issuer also issued Series D common stock purchase warrants (\"New Series D Warrants\") in consideration for the Exercise. The Offering closed on June 3, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the exercise of 375,000 Series C warrants for 375,000 Series C Units, consisting of an aggregate of (i) 375,000 shares of common stock and (ii) Series C-1 Warrants to purchase up to an aggregate of 375,000 shares of common stock. The Series C Warrants are exercisable immediately upon issuance and will expire four months from April 18, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents the exercise of 375,000 Series C warrants for 375,000 Series C Units, consisting of an aggregate of (i) 375,000 shares of common stock and (ii) Series C-1 Warrants to purchase up to an aggregate of 375,000 shares of common stock. The Series C Warrants are exercisable immediately upon issuance and will expire four months from April 18, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":0.2,"expiration_date":"2024-08-18","underlying":"Series C Unit","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001493152-24-022745","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224022745/ownership.xml","form_type":"4"}},{"id":1490247,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2024-06-05T20:15:09.000Z","date":"2024-06-03","kind":"exercise","planned":false,"acquired":true,"shares":173000,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On May 31, 2024, the Reporting Person and the Issuer entered into an inducement offer letter agreement (the \"Inducement Agreement\") providing for the immediate exercise of some or all of certain Series B warrants and Series C warrants, at an initial exercise price of $0.60, previously purchased in the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"), at a reduced exercise price of $0.20 (the \"Exercise\"). Pursuant to the Inducement Agreement, the Issuer also issued Series D common stock purchase warrants (\"New Series D Warrants\") in consideration for the Exercise. The Offering closed on June 3, 2024."},{"field":"security","element":"securityTitle","label":"F2","text":"Represents the exercise of 173,000 Series B warrants for 173,000 Series B Units, consisting of an aggregate of (i) 173,000 shares of common stock and (ii) Series B-1 Warrants to purchase up to an aggregate of 173,000 shares of common stock. The Series B Warrants are exercisable immediately upon issuance and will expire twelve months from April 18, 2024."},{"field":"security","element":"securityTitle","label":"F3","text":"The Series B-1 Warrants are exercisable immediately upon issuance and are exercisable for a term of 5 years from June 3, 2024 (the \"Issuance Date\") at a reduced exercise price of $0.20."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B-1 Warrants are exercisable immediately upon issuance and are exercisable for a term of 5 years from June 3, 2024 (the \"Issuance Date\") at a reduced exercise price of $0.20."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B-1 Warrants are exercisable immediately upon issuance and are exercisable for a term of 5 years from June 3, 2024 (the \"Issuance Date\") at a reduced exercise price of $0.20."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":173000,"derivative":{"exercise_price":0.2,"expiration_date":"2029-06-03","underlying":"Common Stock","underlying_shares":173000},"source":{"system":"sec-edgar","filing":"0001493152-24-022745","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224022745/ownership.xml","form_type":"4"}},{"id":1490246,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2024-06-05T20:15:09.000Z","date":"2024-06-03","kind":"exercise","planned":false,"acquired":false,"shares":173000,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On May 31, 2024, the Reporting Person and the Issuer entered into an inducement offer letter agreement (the \"Inducement Agreement\") providing for the immediate exercise of some or all of certain Series B warrants and Series C warrants, at an initial exercise price of $0.60, previously purchased in the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"), at a reduced exercise price of $0.20 (the \"Exercise\"). Pursuant to the Inducement Agreement, the Issuer also issued Series D common stock purchase warrants (\"New Series D Warrants\") in consideration for the Exercise. The Offering closed on June 3, 2024."},{"field":"security","element":"securityTitle","label":"F2","text":"Represents the exercise of 173,000 Series B warrants for 173,000 Series B Units, consisting of an aggregate of (i) 173,000 shares of common stock and (ii) Series B-1 Warrants to purchase up to an aggregate of 173,000 shares of common stock. The Series B Warrants are exercisable immediately upon issuance and will expire twelve months from April 18, 2024."},{"field":"security","element":"securityTitle","label":"F3","text":"The Series B-1 Warrants are exercisable immediately upon issuance and are exercisable for a term of 5 years from June 3, 2024 (the \"Issuance Date\") at a reduced exercise price of $0.20."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2024, the Reporting Person and the Issuer entered into an inducement offer letter agreement (the \"Inducement Agreement\") providing for the immediate exercise of some or all of certain Series B warrants and Series C warrants, at an initial exercise price of $0.60, previously purchased in the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"), at a reduced exercise price of $0.20 (the \"Exercise\"). Pursuant to the Inducement Agreement, the Issuer also issued Series D common stock purchase warrants (\"New Series D Warrants\") in consideration for the Exercise. The Offering closed on June 3, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the exercise of 173,000 Series B warrants for 173,000 Series B Units, consisting of an aggregate of (i) 173,000 shares of common stock and (ii) Series B-1 Warrants to purchase up to an aggregate of 173,000 shares of common stock. The Series B Warrants are exercisable immediately upon issuance and will expire twelve months from April 18, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents the exercise of 173,000 Series B warrants for 173,000 Series B Units, consisting of an aggregate of (i) 173,000 shares of common stock and (ii) Series B-1 Warrants to purchase up to an aggregate of 173,000 shares of common stock. The Series B Warrants are exercisable immediately upon issuance and will expire twelve months from April 18, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":202000,"derivative":{"exercise_price":0.2,"expiration_date":"2025-04-18","underlying":"Series B Unit","underlying_shares":173000},"source":{"system":"sec-edgar","filing":"0001493152-24-022745","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224022745/ownership.xml","form_type":"4"}},{"id":1490245,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T20:15:09.000Z","date":"2024-06-03","kind":"exercise","planned":false,"acquired":true,"shares":375000,"price":0.2,"value":75000.0,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On May 31, 2024, the Reporting Person and the Issuer entered into an inducement offer letter agreement (the \"Inducement Agreement\") providing for the immediate exercise of some or all of certain Series B warrants and Series C warrants, at an initial exercise price of $0.60, previously purchased in the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"), at a reduced exercise price of $0.20 (the \"Exercise\"). Pursuant to the Inducement Agreement, the Issuer also issued Series D common stock purchase warrants (\"New Series D Warrants\") in consideration for the Exercise. The Offering closed on June 3, 2024."},{"field":"security","element":"securityTitle","label":"F2","text":"Represents the exercise of 173,000 Series B warrants for 173,000 Series B Units, consisting of an aggregate of (i) 173,000 shares of common stock and (ii) Series B-1 Warrants to purchase up to an aggregate of 173,000 shares of common stock. The Series B Warrants are exercisable immediately upon issuance and will expire twelve months from April 18, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":963887,"source":{"system":"sec-edgar","filing":"0001493152-24-022745","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224022745/ownership.xml","form_type":"4"}},{"id":1490244,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T20:15:09.000Z","date":"2024-06-03","kind":"exercise","planned":false,"acquired":true,"shares":173000,"price":0.2,"value":34600.0,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On May 31, 2024, the Reporting Person and the Issuer entered into an inducement offer letter agreement (the \"Inducement Agreement\") providing for the immediate exercise of some or all of certain Series B warrants and Series C warrants, at an initial exercise price of $0.60, previously purchased in the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"), at a reduced exercise price of $0.20 (the \"Exercise\"). Pursuant to the Inducement Agreement, the Issuer also issued Series D common stock purchase warrants (\"New Series D Warrants\") in consideration for the Exercise. The Offering closed on June 3, 2024."},{"field":"security","element":"securityTitle","label":"F2","text":"Represents the exercise of 173,000 Series B warrants for 173,000 Series B Units, consisting of an aggregate of (i) 173,000 shares of common stock and (ii) Series B-1 Warrants to purchase up to an aggregate of 173,000 shares of common stock. The Series B Warrants are exercisable immediately upon issuance and will expire twelve months from April 18, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":588887,"source":{"system":"sec-edgar","filing":"0001493152-24-022745","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224022745/ownership.xml","form_type":"4"}},{"id":1537644,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2024-04-22T21:00:39.000Z","date":"2024-04-18","kind":"grant","planned":false,"acquired":true,"shares":375000,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents 375,000 shares of common stock acquired by the Reporting Person at the public offering price of $0.40 per Common Stock Unit, each consisting of: (i) one share of common stock, (ii) one Series A warrant, (iii) one Series B warrant, and (iv) one Series C warrant, for a total purchase price of $150,000, in connection with the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"). The Units were acquired in a transaction exempt under Rule 16b-3 and at the same offering terms as other investors in the Offering."},{"field":"security","element":"securityTitle","label":"F4","text":"Represents 375,000 Series C warrants to purchase 375,000 Series C Units (the \"Series C Warrants\"), at an exercise price of $0.60 per Series C Unit, with each Series C Unit consisting of (i) one share of the common stock and (ii) one Series C-1 Warrant to purchase one share of common stock, at an exercise price of $0.60. The Series C-1 Warrants will only be issued upon exercise of the Series B Warrants, and will expire five years from the date of such issuance. The Series C Warrants are exercisable immediately upon issuance and will expire four months from April 18, 2024, the date of issuance of the Series C Warrants."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents 375,000 Series C warrants to purchase 375,000 Series C Units (the \"Series C Warrants\"), at an exercise price of $0.60 per Series C Unit, with each Series C Unit consisting of (i) one share of the common stock and (ii) one Series C-1 Warrant to purchase one share of common stock, at an exercise price of $0.60. The Series C-1 Warrants will only be issued upon exercise of the Series B Warrants, and will expire five years from the date of such issuance. The Series C Warrants are exercisable immediately upon issuance and will expire four months from April 18, 2024, the date of issuance of the Series C Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents 375,000 Series C warrants to purchase 375,000 Series C Units (the \"Series C Warrants\"), at an exercise price of $0.60 per Series C Unit, with each Series C Unit consisting of (i) one share of the common stock and (ii) one Series C-1 Warrant to purchase one share of common stock, at an exercise price of $0.60. The Series C-1 Warrants will only be issued upon exercise of the Series B Warrants, and will expire five years from the date of such issuance. The Series C Warrants are exercisable immediately upon issuance and will expire four months from April 18, 2024, the date of issuance of the Series C Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":375000,"derivative":{"exercise_price":0.6,"expiration_date":"2024-08-18","underlying":"Series C Unit","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001493152-24-015572","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224015572/ownership.xml","form_type":"4"}},{"id":1537643,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2024-04-22T21:00:39.000Z","date":"2024-04-18","kind":"grant","planned":false,"acquired":true,"shares":375000,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents 375,000 shares of common stock acquired by the Reporting Person at the public offering price of $0.40 per Common Stock Unit, each consisting of: (i) one share of common stock, (ii) one Series A warrant, (iii) one Series B warrant, and (iv) one Series C warrant, for a total purchase price of $150,000, in connection with the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"). The Units were acquired in a transaction exempt under Rule 16b-3 and at the same offering terms as other investors in the Offering."},{"field":"security","element":"securityTitle","label":"F3","text":"Represents 375,000 Series B warrants to purchase 375,000 Series B Unit (the \"Series B Warrants\"), at an exercise price of $0.60 per Series B Unit, with each Series B Unit consisting of (i) one share of the common stock and (ii) one Series B-1 Warrant to purchase one share of common stock, at an exercise price of $0.60. The Series B-1 Warrants will only be issued upon exercise of the Series B Warrants, and will expire five years from the date of such issuance. The Series B Warrants are exercisable immediately upon issuance and will expire twelve months from April 18, 2024, the date of issuance of the Series B Warrants."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents 375,000 Series B warrants to purchase 375,000 Series B Unit (the \"Series B Warrants\"), at an exercise price of $0.60 per Series B Unit, with each Series B Unit consisting of (i) one share of the common stock and (ii) one Series B-1 Warrant to purchase one share of common stock, at an exercise price of $0.60. The Series B-1 Warrants will only be issued upon exercise of the Series B Warrants, and will expire five years from the date of such issuance. The Series B Warrants are exercisable immediately upon issuance and will expire twelve months from April 18, 2024, the date of issuance of the Series B Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents 375,000 Series B warrants to purchase 375,000 Series B Unit (the \"Series B Warrants\"), at an exercise price of $0.60 per Series B Unit, with each Series B Unit consisting of (i) one share of the common stock and (ii) one Series B-1 Warrant to purchase one share of common stock, at an exercise price of $0.60. The Series B-1 Warrants will only be issued upon exercise of the Series B Warrants, and will expire five years from the date of such issuance. The Series B Warrants are exercisable immediately upon issuance and will expire twelve months from April 18, 2024, the date of issuance of the Series B Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":375000,"derivative":{"exercise_price":0.6,"expiration_date":"2025-04-18","underlying":"Series B Unit","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001493152-24-015572","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224015572/ownership.xml","form_type":"4"}},{"id":1537642,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2024-04-22T21:00:39.000Z","date":"2024-04-18","kind":"grant","planned":false,"acquired":true,"shares":375000,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents 375,000 shares of common stock acquired by the Reporting Person at the public offering price of $0.40 per Common Stock Unit, each consisting of: (i) one share of common stock, (ii) one Series A warrant, (iii) one Series B warrant, and (iv) one Series C warrant, for a total purchase price of $150,000, in connection with the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"). The Units were acquired in a transaction exempt under Rule 16b-3 and at the same offering terms as other investors in the Offering."},{"field":"security","element":"securityTitle","label":"F2","text":"Represents 375,000 Series A warrants to purchase 375,000 shares of common stock at an exercise price of $0.60 per share (the \"Series A Warrants\"). The Series A Warrants are exercisable immediately upon issuance and will expire five years from April 18, 2024, the date of issuance of the Series A Warrants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents 375,000 Series A warrants to purchase 375,000 shares of common stock at an exercise price of $0.60 per share (the \"Series A Warrants\"). The Series A Warrants are exercisable immediately upon issuance and will expire five years from April 18, 2024, the date of issuance of the Series A Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents 375,000 Series A warrants to purchase 375,000 shares of common stock at an exercise price of $0.60 per share (the \"Series A Warrants\"). The Series A Warrants are exercisable immediately upon issuance and will expire five years from April 18, 2024, the date of issuance of the Series A Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":375000,"derivative":{"exercise_price":0.6,"expiration_date":"2029-04-18","underlying":"Common Stock","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001493152-24-015572","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224015572/ownership.xml","form_type":"4"}},{"id":1537641,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-22T21:00:39.000Z","date":"2024-04-18","kind":"grant","planned":false,"acquired":true,"shares":375000,"price":0.4,"value":150000.0,"ownership":{"direct":false,"nature":"By James & Cynthia Schoeneck Family Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents 375,000 shares of common stock acquired by the Reporting Person at the public offering price of $0.40 per Common Stock Unit, each consisting of: (i) one share of common stock, (ii) one Series A warrant, (iii) one Series B warrant, and (iv) one Series C warrant, for a total purchase price of $150,000, in connection with the Issuer's public offering which closed on April 18, 2024 (the \"Offering\"). The Units were acquired in a transaction exempt under Rule 16b-3 and at the same offering terms as other investors in the Offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held by James & Cynthia Schoeneck Family Trust (the \"Trust\"). Mr. Schoeneck is a trustee of the Trust, and may be deemed to beneficially own the securities held by the Trust. Mr. Schoeneck disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":415887,"source":{"system":"sec-edgar","filing":"0001493152-24-015572","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224015572/ownership.xml","form_type":"4"}},{"id":1688269,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2024-01-05T00:51:34.000Z","date":"2023-12-21","kind":"grant","planned":false,"acquired":true,"shares":70249,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on December 21, 2023 (the \"Grant Date\"), the Reporting Person was granted 70,249 Non-Qualified Stock Options (the \"Options\") at an exercise price of $1.80, which is equal to the closing price of the Issuer's common stock on December 21, 2023, for serving as a director. The Options will vest in one year or next annual shareholder meeting, whichever first. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\"), on December 21, 2023 (the \"Grant Date\"), the Reporting Person was granted 70,249 Non-Qualified Stock Options (the \"Options\") at an exercise price of $1.80, which is equal to the closing price of the Issuer's common stock on December 21, 2023, for serving as a director. The Options will vest in one year or next annual shareholder meeting, whichever first. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person."}],"balance_after":70249,"derivative":{"exercise_price":1.8,"expiration_date":"2033-12-21","underlying":"Common stock","underlying_shares":70249},"source":{"system":"sec-edgar","filing":"0001493152-24-001134","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224001134/ownership.xml","form_type":"4"}},{"id":1688268,"issuer":{"id":8408,"kind":"organization","name":"Calidi Biotherapeutics, Inc."},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-05T00:51:34.000Z","date":"2023-12-21","kind":"grant","planned":false,"acquired":true,"shares":10625,"price":1.8,"value":19125.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents a grant of restricted stock units (\"RSUs\") subject to the conditions of the Restricted Stock Unit Award Agreement pursuant to the Issuer's 2023 Plan. Each RSU represents a right to receive one share of the Company's common stock upon vesting. The number of RSUs to be issued will equal to the amount due to the director for Board fees divided by the closing price for a share of the Issuer's common stock. The RSUs were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. The shares of common stock underlying the RSUs immediately vested on the Grant Date."}],"balance_after":27872,"source":{"system":"sec-edgar","filing":"0001493152-24-001134","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224001134/ownership.xml","form_type":"4"}},{"id":1809077,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-14T21:00:43.000Z","date":"2023-08-10","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10000,"derivative":{"exercise_price":1.44,"exercise_date":"2023-11-01","expiration_date":"2033-08-10","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-23-045673","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919123045673/doc4.xml","form_type":"4"}},{"id":1861267,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T23:51:43.000Z","date":"2023-06-07","kind":"grant","planned":true,"acquired":true,"shares":12666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":12666,"derivative":{"exercise_price":17.13,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":12666},"source":{"system":"sec-edgar","filing":"0001209191-23-036073","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919123036073/doc4.xml","form_type":"4"}},{"id":1861266,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T23:51:43.000Z","date":"2023-06-07","kind":"sale","planned":true,"acquired":false,"shares":7100,"price":18.0264,"value":127987.44,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares sold by the reporting person (pursuant to a 10b5-1 trading plan dated March 2, 2023) to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Price reported is a weighted-average sales price. The shares were sold at prices ranging from $17.77 to $18.56. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":73722,"source":{"system":"sec-edgar","filing":"0001209191-23-036073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919123036073/doc4.xml","form_type":"4"}},{"id":1861265,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T23:51:43.000Z","date":"2023-06-07","kind":"grant","planned":true,"acquired":true,"shares":8289,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":28766,"source":{"system":"sec-edgar","filing":"0001209191-23-036073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919123036073/doc4.xml","form_type":"4"}},{"id":2226079,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T01:05:18.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":25684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options vest on the earlier of June 16, 2023 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":25684,"derivative":{"exercise_price":9,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":25684},"source":{"system":"sec-edgar","filing":"0001209191-22-038598","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919122038598/doc4.xml","form_type":"4"}},{"id":2226078,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-22T01:05:18.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":15777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest on the earlier of June 16, 2023 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":20477,"source":{"system":"sec-edgar","filing":"0001209191-22-038598","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919122038598/doc4.xml","form_type":"4"}},{"id":2692030,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-28T23:09:23.000Z","date":"2021-05-26","kind":"grant","acquired":true,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":7800,"derivative":{"exercise_price":20.86,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":7800},"source":{"system":"sec-edgar","filing":"0001209191-21-036684","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919121036684/doc4.xml","form_type":"4"}},{"id":2692029,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-28T23:09:23.000Z","date":"2021-05-26","kind":"grant","acquired":true,"shares":4700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":14100,"source":{"system":"sec-edgar","filing":"0001209191-21-036684","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919121036684/doc4.xml","form_type":"4"}},{"id":2917143,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-07T00:08:13.000Z","date":"2021-01-04","kind":"exercise","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":9.775,"expiration_date":"2023-04-17","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-21-002361","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919121002361/doc4.xml","form_type":"4"}},{"id":2917142,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-07T00:08:13.000Z","date":"2021-01-04","kind":"exercise","acquired":true,"shares":6000,"price":9.775,"value":58650.0,"ownership":{"direct":true},"balance_after":15400,"source":{"system":"sec-edgar","filing":"0001209191-21-002361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919121002361/doc4.xml","form_type":"4"}},{"id":3050293,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-21T21:58:55.000Z","date":"2020-08-20","kind":"exercise","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":5.95,"expiration_date":"2022-06-27","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-20-047985","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919120047985/doc4.xml","form_type":"4"}},{"id":3050292,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-21T21:58:55.000Z","date":"2020-08-20","kind":"exercise","acquired":true,"shares":6000,"price":5.95,"value":35700.0,"ownership":{"direct":true},"balance_after":15400,"source":{"system":"sec-edgar","filing":"0001209191-20-047985","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919120047985/doc4.xml","form_type":"4"}},{"id":3119309,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-09T00:34:54.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options vest on the earlier of June 4, 2021 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":7800,"derivative":{"exercise_price":32.69,"expiration_date":"2030-06-03","underlying":"Common Stock","underlying_shares":7800},"source":{"system":"sec-edgar","filing":"0001209191-20-035158","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919120035158/doc4.xml","form_type":"4"}},{"id":3119308,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-09T00:34:54.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":4700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest on the earlier of June 4, 2021 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":9400,"source":{"system":"sec-edgar","filing":"0001209191-20-035158","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919120035158/doc4.xml","form_type":"4"}},{"id":3315681,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim President"}}],"security":"Common Stock","published_at":"2020-01-09T02:16:48.000Z","date":"2020-01-06","kind":"tax_withholding","acquired":false,"shares":10928,"price":43.35,"value":473728.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the cancellation on January 6, 2020 of 28,650 shares pursuant to the vesting terms of the RSU grant."}],"balance_after":22422,"source":{"system":"sec-edgar","filing":"0001209191-20-002653","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919120002653/doc4.xml","form_type":"4"}},{"id":3409308,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-09-20T22:00:12.000Z","date":"2019-09-18","kind":"grant","acquired":true,"shares":97100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The vesting schedule for the stock option and RSU grants, which shall have a Vesting Base date of August 26, 2019, is as follows: 50% of the Awards shall vest on the earlier of February 26, 2020 or upon the hiring of a new CEO, and 50% shall vest on August 26, 2020, subject to continued service as Interim CEO, provided that if Mr. Schoeneck's Interim CEO service terminates between February 26, 2020 and August 26, 2020, the Awards vest pro-rata based on the number of months of Interim CEO service past February 26, 2020 (rounding up for partial months) as a fraction of the 6-month period at the time service terminates."}],"balance_after":97100,"derivative":{"exercise_price":40.96,"expiration_date":"2029-09-18","underlying":"Common Stock","underlying_shares":97100},"source":{"system":"sec-edgar","filing":"0001209191-19-050376","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119050376/doc4.xml","form_type":"4"}},{"id":3409307,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Common Stock","published_at":"2019-09-20T22:00:12.000Z","date":"2019-09-18","kind":"grant","acquired":true,"shares":57300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The vesting schedule for the stock option and RSU grants, which shall have a Vesting Base date of August 26, 2019, is as follows: 50% of the Awards shall vest on the earlier of February 26, 2020 or upon the hiring of a new CEO, and 50% shall vest on August 26, 2020, subject to continued service as Interim CEO, provided that if Mr. Schoeneck's Interim CEO service terminates between February 26, 2020 and August 26, 2020, the Awards vest pro-rata based on the number of months of Interim CEO service past February 26, 2020 (rounding up for partial months) as a fraction of the 6-month period at the time service terminates."}],"balance_after":62000,"source":{"system":"sec-edgar","filing":"0001209191-19-050376","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119050376/doc4.xml","form_type":"4"}},{"id":3497815,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-07T23:24:46.000Z","date":"2019-06-05","kind":"grant","acquired":true,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options vest on the earlier of June 5, 2020 or the date of the next annual meeting of stockholders."}],"balance_after":7800,"derivative":{"exercise_price":39.03,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":7800},"source":{"system":"sec-edgar","filing":"0001209191-19-035667","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119035667/doc4.xml","form_type":"4"}},{"id":3497814,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-07T23:24:46.000Z","date":"2019-06-05","kind":"grant","acquired":true,"shares":4700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest on the earlier of June 5, 2020 or the date of the next annual meeting of stockholders."}],"balance_after":22400,"source":{"system":"sec-edgar","filing":"0001209191-19-035667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119035667/doc4.xml","form_type":"4"}},{"id":3507977,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-30T21:43:01.000Z","date":"2019-05-28","kind":"exercise","acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":3.5,"expiration_date":"2021-03-15","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-19-033502","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119033502/doc4.xml","form_type":"4"}},{"id":3507976,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-30T21:43:01.000Z","date":"2019-05-28","kind":"exercise","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":2.9,"expiration_date":"2020-04-27","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001209191-19-033502","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119033502/doc4.xml","form_type":"4"}},{"id":3507975,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-30T21:43:01.000Z","date":"2019-05-28","kind":"exercise","acquired":true,"shares":12000,"price":3.5,"value":42000.0,"ownership":{"direct":true},"balance_after":17700,"source":{"system":"sec-edgar","filing":"0001209191-19-033502","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119033502/doc4.xml","form_type":"4"}},{"id":3507974,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-30T21:43:01.000Z","date":"2019-05-28","kind":"exercise","acquired":true,"shares":2000,"price":2.9,"value":5800.0,"ownership":{"direct":true},"balance_after":5700,"source":{"system":"sec-edgar","filing":"0001209191-19-033502","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119033502/doc4.xml","form_type":"4"}},{"id":3534033,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-10T01:00:24.000Z","date":"2019-05-07","kind":"exercise","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Fully vested."}],"balance_after":2000,"derivative":{"exercise_price":2.9,"expiration_date":"2020-04-27","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001209191-19-028663","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119028663/doc4.xml","form_type":"4"}},{"id":3534032,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-10T01:00:24.000Z","date":"2019-05-07","kind":"sale","acquired":false,"shares":500,"price":47.69,"value":23845.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were sold at prices ranging from $47.27 to $48.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":3700,"source":{"system":"sec-edgar","filing":"0001209191-19-028663","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119028663/doc4.xml","form_type":"4"}},{"id":3534031,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-10T01:00:24.000Z","date":"2019-05-07","kind":"sale","acquired":false,"shares":1500,"price":46.8,"value":70200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $46.16 to $47.14. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":4200,"source":{"system":"sec-edgar","filing":"0001209191-19-028663","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119028663/doc4.xml","form_type":"4"}},{"id":3534030,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-10T01:00:24.000Z","date":"2019-05-07","kind":"exercise","acquired":true,"shares":2000,"price":2.9,"value":5800.0,"ownership":{"direct":true},"balance_after":5700,"source":{"system":"sec-edgar","filing":"0001209191-19-028663","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119028663/doc4.xml","form_type":"4"}},{"id":3558826,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-10T23:43:32.000Z","date":"2019-04-08","kind":"exercise","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Fully vested."}],"balance_after":4000,"derivative":{"exercise_price":2.9,"expiration_date":"2020-04-27","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001209191-19-024314","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119024314/doc4.xml","form_type":"4"}},{"id":3558825,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-10T23:43:32.000Z","date":"2019-04-08","kind":"sale","acquired":false,"shares":2000,"price":52.9,"value":105800.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $52.69 to $53.27. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":27700,"source":{"system":"sec-edgar","filing":"0001209191-19-024314","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119024314/doc4.xml","form_type":"4"}},{"id":3558824,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-10T23:43:32.000Z","date":"2019-04-08","kind":"exercise","acquired":true,"shares":2000,"price":2.9,"value":5800.0,"ownership":{"direct":true},"balance_after":29700,"source":{"system":"sec-edgar","filing":"0001209191-19-024314","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119024314/doc4.xml","form_type":"4"}},{"id":3605002,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-08T23:47:15.000Z","date":"2019-03-07","kind":"exercise","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Fully vested."}],"balance_after":6000,"derivative":{"exercise_price":2.9,"expiration_date":"2020-04-27","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001209191-19-018278","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119018278/doc4.xml","form_type":"4"}},{"id":3605001,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-08T23:47:15.000Z","date":"2019-03-07","kind":"sale","acquired":false,"shares":380,"price":55.23,"value":20987.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were sold at prices ranging from $55.05 to $55.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":27700,"source":{"system":"sec-edgar","filing":"0001209191-19-018278","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119018278/doc4.xml","form_type":"4"}},{"id":3605000,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-08T23:47:15.000Z","date":"2019-03-07","kind":"sale","acquired":false,"shares":1620,"price":54.62,"value":88484.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $54.05 to $55.04. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":28080,"source":{"system":"sec-edgar","filing":"0001209191-19-018278","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119018278/doc4.xml","form_type":"4"}},{"id":3604999,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-08T23:47:15.000Z","date":"2019-03-07","kind":"exercise","acquired":true,"shares":2000,"price":2.9,"value":5800.0,"ownership":{"direct":true},"balance_after":29700,"source":{"system":"sec-edgar","filing":"0001209191-19-018278","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119018278/doc4.xml","form_type":"4"}},{"id":3669039,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-09T00:00:05.000Z","date":"2019-02-07","kind":"exercise","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":8000,"derivative":{"exercise_price":2.9,"expiration_date":"2020-04-27","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001209191-19-008746","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119008746/doc4.xml","form_type":"4"}},{"id":3669038,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-09T00:00:05.000Z","date":"2019-02-07","kind":"sale","acquired":false,"shares":2000,"price":57.17,"value":114340.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 plan."}],"balance_after":27700,"source":{"system":"sec-edgar","filing":"0001209191-19-008746","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119008746/doc4.xml","form_type":"4"}},{"id":3669037,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-09T00:00:05.000Z","date":"2019-02-07","kind":"exercise","acquired":true,"shares":2000,"price":2.9,"value":5800.0,"ownership":{"direct":true},"balance_after":29700,"source":{"system":"sec-edgar","filing":"0001209191-19-008746","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119008746/doc4.xml","form_type":"4"}},{"id":3699376,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-09T23:48:41.000Z","date":"2019-01-07","kind":"exercise","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":10000,"derivative":{"exercise_price":2.9,"expiration_date":"2020-04-27","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001209191-19-003154","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119003154/doc4.xml","form_type":"4"}},{"id":3699375,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-09T23:48:41.000Z","date":"2019-01-07","kind":"sale","acquired":false,"shares":2000,"price":45.9,"value":91800.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 plan."}],"balance_after":27700,"source":{"system":"sec-edgar","filing":"0001209191-19-003154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119003154/doc4.xml","form_type":"4"}},{"id":3699374,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-09T23:48:41.000Z","date":"2019-01-07","kind":"exercise","acquired":true,"shares":2000,"price":2.9,"value":5800.0,"ownership":{"direct":true},"balance_after":29700,"source":{"system":"sec-edgar","filing":"0001209191-19-003154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119003154/doc4.xml","form_type":"4"}},{"id":3778426,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (RIght to Buy)","published_at":"2018-11-01T17:48:04.000Z","date":"2018-10-30","kind":"exercise","acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-18-056739","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919118056739/doc4.xml","form_type":"4"}},{"id":3778425,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-01T17:48:04.000Z","date":"2018-10-30","kind":"exercise","acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":9.775,"expiration_date":"2023-04-17","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-18-056739","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919118056739/doc4.xml","form_type":"4"}},{"id":3778424,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-01T17:48:04.000Z","date":"2018-10-30","kind":"exercise","acquired":true,"shares":12000,"price":18,"value":216000.0,"ownership":{"direct":true},"balance_after":27700,"source":{"system":"sec-edgar","filing":"0001209191-18-056739","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919118056739/doc4.xml","form_type":"4"}},{"id":3778423,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-01T17:48:04.000Z","date":"2018-10-30","kind":"exercise","acquired":true,"shares":12000,"price":9.775,"value":117300.0,"ownership":{"direct":true},"balance_after":15700,"source":{"system":"sec-edgar","filing":"0001209191-18-056739","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919118056739/doc4.xml","form_type":"4"}},{"id":3872015,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-07-07T00:04:11.000Z","date":"2018-07-03","kind":"exercise","acquired":false,"shares":7639,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":12000,"derivative":{"exercise_price":2.9,"expiration_date":"2020-04-27","underlying":"Common Stock","underlying_shares":7639},"source":{"system":"sec-edgar","filing":"0001209191-18-041916","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919118041916/doc4.xml","form_type":"4"}},{"id":3872014,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-07T00:04:11.000Z","date":"2018-07-03","kind":"sale","acquired":false,"shares":7639,"price":65,"value":496535.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 plan."}],"balance_after":3700,"source":{"system":"sec-edgar","filing":"0001209191-18-041916","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919118041916/doc4.xml","form_type":"4"}},{"id":3872013,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-07T00:04:11.000Z","date":"2018-07-03","kind":"exercise","acquired":true,"shares":7639,"price":2.9,"value":22153.1,"ownership":{"direct":true},"balance_after":11339,"source":{"system":"sec-edgar","filing":"0001209191-18-041916","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919118041916/doc4.xml","form_type":"4"}},{"id":3883456,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-27T00:02:32.000Z","date":"2018-06-22","kind":"exercise","acquired":false,"shares":4361,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":19639,"derivative":{"exercise_price":2.9,"expiration_date":"2020-04-27","underlying":"Common Stock","underlying_shares":4361},"source":{"system":"sec-edgar","filing":"0001209191-18-039547","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919118039547/doc4.xml","form_type":"4"}},{"id":3883455,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-27T00:02:32.000Z","date":"2018-06-22","kind":"sale","acquired":false,"shares":4361,"price":65,"value":283465.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 plan."}],"balance_after":3700,"source":{"system":"sec-edgar","filing":"0001209191-18-039547","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919118039547/doc4.xml","form_type":"4"}},{"id":3883454,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-27T00:02:32.000Z","date":"2018-06-22","kind":"exercise","acquired":true,"shares":4361,"price":2.9,"value":12646.9,"ownership":{"direct":true},"balance_after":8061,"source":{"system":"sec-edgar","filing":"0001209191-18-039547","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919118039547/doc4.xml","form_type":"4"}},{"id":3902438,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-07T23:45:32.000Z","date":"2018-06-05","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options vest on the earlier of June 6, 2019 or the date of the next annual meeting of stockholders."}],"balance_after":6000,"derivative":{"exercise_price":55.3,"expiration_date":"2028-06-05","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-18-036521","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919118036521/doc4.xml","form_type":"4"}},{"id":3902437,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-07T23:45:32.000Z","date":"2018-06-05","kind":"grant","acquired":true,"shares":3700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest on the earlier of June 6, 2019 or the date of the next annual meeting of stockholders."}],"balance_after":3700,"source":{"system":"sec-edgar","filing":"0001209191-18-036521","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919118036521/doc4.xml","form_type":"4"}},{"id":4073662,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2018-02-06T21:18:32.000Z","date":"2018-02-02","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 2, 2018, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":6000,"derivative":{"exercise_price":104.81,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-18-007835","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1420987/000120919118007835/doc4.xml","form_type":"4"}},{"id":4287577,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-09T22:43:55.000Z","date":"2017-06-07","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest and become exercisable quarterly over one year measured from June 7, 2017."}],"balance_after":12000,"derivative":{"exercise_price":28.65,"expiration_date":"2027-06-07","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-17-039003","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919117039003/doc4.xml","form_type":"4"}},{"id":4417498,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2017-02-28T23:59:39.000Z","date":"2017-02-24","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes fully exercisable on February 24, 2018."}],"balance_after":15000,"derivative":{"exercise_price":24.6,"expiration_date":"2027-02-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-17-015465","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1420987/000120919117015465/doc4.xml","form_type":"4"}},{"id":4457790,"issuer":{"id":149352,"kind":"organization","name":"Assertio Therapeutics, Inc","symbol":"ASRT"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-11T00:40:47.000Z","date":"2016-10-12","kind":"gift","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Family Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Charitable transfer of shares from family trust."}],"balance_after":495105,"source":{"system":"sec-edgar","filing":"0001179110-17-002206","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005201/000117911017002206/edgar.xml","form_type":"5"}},{"id":4457981,"issuer":{"id":149352,"kind":"organization","name":"Assertio Therapeutics, Inc","symbol":"ASRT"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options","published_at":"2017-02-11T00:39:19.000Z","date":"2017-02-08","kind":"grant","acquired":true,"shares":245000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options are exercisable in 48 equal monthly installments."}],"balance_after":245000,"derivative":{"exercise_price":17.09,"expiration_date":"2027-02-08","underlying":"Common Stock","underlying_shares":245000},"source":{"system":"sec-edgar","filing":"0001179110-17-002204","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005201/000117911017002204/edgar.xml","form_type":"4"}},{"id":4457980,"issuer":{"id":149352,"kind":"organization","name":"Assertio Therapeutics, Inc","symbol":"ASRT"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2017-02-11T00:39:19.000Z","date":"2017-02-08","kind":"grant","acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units are scheduled to vest 25% on December 1, 2017, 25% on December 1, 2018, 25% on December 1, 2019, and 25% on December 1, 2020, assuming continued employment through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These restricted stock units are scheduled to vest 25% on December 1, 2017, 25% on December 1, 2018, 25% on December 1, 2019, and 25% on December 1, 2020, assuming continued employment through the applicable vesting date."}],"balance_after":105000,"derivative":{"underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001179110-17-002204","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005201/000117911017002204/edgar.xml","form_type":"4"}},{"id":4512030,"issuer":{"id":149352,"kind":"organization","name":"Assertio Therapeutics, Inc","symbol":"ASRT"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2016-12-27T21:21:47.000Z","date":"2016-12-23","kind":"gift","acquired":true,"shares":61207,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transfer of shares to family trust."},{"field":"shares","element":"transactionShares","label":"F1","text":"Transfer of shares to family trust."}],"balance_after":495105,"source":{"system":"sec-edgar","filing":"0001179110-16-033463","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005201/000117911016033463/edgar.xml","form_type":"4"}},{"id":4512029,"issuer":{"id":149352,"kind":"organization","name":"Assertio Therapeutics, Inc","symbol":"ASRT"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2016-12-27T21:21:47.000Z","date":"2016-12-23","kind":"gift","acquired":false,"shares":61207,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transfer of shares to family trust."},{"field":"shares","element":"transactionShares","label":"F1","text":"Transfer of shares to family trust."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-16-033463","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005201/000117911016033463/edgar.xml","form_type":"4"}},{"id":4531996,"issuer":{"id":149352,"kind":"organization","name":"Assertio Therapeutics, Inc","symbol":"ASRT"},"owners":[{"id":21678,"kind":"person","name":"Schoeneck James A","position":1,"cik":"0001420987","reported_name":"Schoeneck James A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2016-12-06T23:59:29.000Z","date":"2016-12-01","kind":"tax_withholding","acquired":false,"shares":66793,"price":18.55,"value":1239010.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock forfeited to meet the tax liability triggered by the vesting of such restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount does not include any unvested restricted stock previously reported on Form 4 by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount does not include 433,898 shares of common stock held indirectly by family trust."}],"balance_after":61207,"source":{"system":"sec-edgar","filing":"0001179110-16-032500","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005201/000117911016032500/edgar.xml","form_type":"4"}}]}